Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ANIX Stock Summary
Top 10 Correlated ETFs
ANIX
In the News

Is Anixa Biosciences (ANIX) Outperforming Other Medical Stocks This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Intuitive Surgical, Inc. (ISRG) have performed compared to their sector so far this year.

Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine
Anixa: I Am More Bullish After Efficacy Data For Its Triple-Negative Breast Cancer Vaccine

Anixa (ANIX) Falls 25% Despite Positive Breast Cancer Study Data
Anixa Biosciences (ANIX) announces positive top-line data from its phase Ia study evaluating the safety of its breast cancer vaccine. However, the stock plunges 25% in the absence of efficacy reports.

What Makes ANIXA BIOSCIENCES INC (ANIX) a Good Fit for "Trend Investing"
ANIXA BIOSCIENCES INC (ANIX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Anixa Biosciences to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SAN JOSE, Calif. , Aug. 31, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it will present a company update at the H.C.

Anixa: Making Sense Of A Bullish Move Up In Bearish Biotech Times
Anixa Biosciences has different very interesting programs ongoing, one of which is a breast cancer vaccine trial with a first partial readout at ASCO in the beginning of June. While the biotech sector has been suffering large losses over the past month, Anixa Biosciences shares have moved up remarkably.

Has Anixa Biosciences (ANIX) Outpaced Other Medical Stocks This Year?
Here is how ANIXA BIOSCIENCES INC (ANIX) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

Anixa (ANIX) COVID Compounds Prove Effective Against Omicron
Anixa Biosciences' (ANIX) potential COVID-19 compounds show effectiveness against the Omicron variant of COVID-19.

Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy
SAN JOSE, Calif., Oct. 1, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa's novel Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology, known as its Chimeric Endocrine Receptor T-cell, or CER-T approach, or more specifically, "Follicle Stimulating Hormone Receptor-Mediated CAR-T technology," which has been licensed from The Wistar Institute and is being developed in partnership with Moffitt Cancer Center.

Anixa Biosciences' Ovarian Cancer CAR-T Therapy to be Discussed at Upcoming Emerging Immunotherapeutics for Ovarian Cancer Symposium
SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the inventor of its ovarian cancer CAR-T technology, Dr. José Conejo-Garcia, Chair of the Immunology Department at Moffitt Cancer Center, will be presenting at the Antibody Society and Ovarian Cancer Research Alliance's Emerging Immunotherapeutics for Ovarian Cancer Symposium on September 23, 2021.
ANIX Financial details
ANIX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-10-31
Metric | History | 2018-10-31 | 2019-10-31 | 2020-10-31 | 2021-10-31 | 2022-10-31 |
---|---|---|---|---|---|---|
Revenue per share | 0.06 | 0.01 | 0 | 0.02 | 81.29 | |
Net income per share | -0.83 | -0.63 | -0.46 | -0.45 | -0.44 | |
Operating cash flow per share | -0.24 | -0.24 | -0.28 | -0.17 | -0.21 | |
Free cash flow per share | -0.24 | -0.25 | -0.28 | -0.17 | -0.21 | |
Cash per share | 0.29 | 0.3 | 0.41 | 1.25 | 0.98 | |
Book value per share | 0.31 | 0.26 | 0.39 | 1.24 | 0.96 | |
Tangible book value per share | 0.25 | 0.24 | 0.37 | 1.22 | 0.93 | |
Share holders equity per share | 0.31 | 0.26 | 0.39 | 1.24 | 0.96 | |
Interest debt per share | 0 | 0 | 0 | 0.01 | 0.01 | |
Market cap | 71.38M | 76.59M | 45.79M | 145.47M | 170.09M | |
Enterprise value | 68.32M | 73.09M | 39.43M | 116.6M | 157.96M | |
P/E ratio | -4.9 | -6.17 | -4.45 | -11.24 | -12.61 | |
Price to sales ratio | 64.16 | 306.35 | 0 | 283.84 | 0.07 | |
POCF ratio | -16.7 | -16.15 | -7.41 | -29.47 | -26.2 | |
PFCF ratio | -16.55 | -15.58 | -7.4 | -29.47 | -26.2 | |
P/B Ratio | 13.13 | 14.63 | 5.23 | 4.1 | 5.86 | |
PTB ratio | 13.13 | 14.63 | 5.23 | 4.1 | 5.86 | |
EV to sales | 61.41 | 292.38 | 0 | 227.51 | 0.06 | |
Enterprise value over EBITDA | -5.13 | -6.9 | -4.05 | -8.91 | -11.42 | |
EV to operating cash flow | -15.99 | -15.42 | -6.38 | -23.62 | -24.33 | |
EV to free cash flow | -15.85 | -14.87 | -6.37 | -23.62 | -24.33 | |
Earnings yield | -0.2 | -0.16 | -0.22 | -0.09 | -0.08 | |
Free cash flow yield | -0.06 | -0.06 | -0.14 | -0.03 | -0.04 | |
Debt to equity | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 0.23 | 0.33 | 0.65 | 2.21 | 0.88 | |
Current ratio | 4.38 | 4.11 | 7.88 | 28.34 | 14.83 | |
Interest coverage | 0 | 0 | 0 | 0 | -133.41 | |
Income quality | 0.3 | 0.4 | 0.61 | 0.38 | 0.47 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 6.21 | 22.65 | 0 | 13.8 | 0 | |
Research and developement to revenue | 6.12 | 21.89 | 0 | 12.08 | 0 | |
Intangibles to total assets | 0.13 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.01 | 0.04 | 0 | 0 | 0 | |
Capex to revenue | -0.03 | -0.7 | 0 | 0 | 0 | |
Capex to depreciation | -0.11 | -0.38 | -0.18 | 0 | 0 | |
Stock based compensation to revenue | 8 | 22.85 | 0 | 15.72 | 0 | |
Graham number | 2.4 | 1.93 | 2.03 | 3.55 | 3.09 | |
ROIC | 57.2 | 9.45 | 2.81 | 0.58 | -2.5 | |
Return on tangible assets | -2.6 | -1.97 | -1.09 | -0.36 | -0.44 | |
Graham Net | 0.22 | 0.22 | 0.35 | 1.2 | 0.9 | |
Working capital | 4.27M | 4.61M | 8.18M | 34.73M | 28.16M | |
Tangible asset value | 4.35M | 4.81M | 8.26M | 34.77M | 28.2M | |
Net current asset value | 4.27M | 4.61M | 8.18M | 34.51M | 27.99M | |
Invested capital | 0 | 0 | 0.01 | 0.01 | 0.01 | |
Average receivables | 0 | 33.26K | 34.38K | 1.12K | 0 | |
Average payables | 531.17K | 583.91K | 409.09K | 184.28K | 200.6K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 97.13 | 0 | 0 | 0 | |
Days payables outstanding | 276.46 | 1.29K | 0 | 129.12 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 3.76 | 0 | 0 | 0 | |
Payables turnover | 1.32 | 0.28 | 0 | 2.83 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -2.68 | -2.37 | -1.17 | -0.37 | -0.46 | |
Capex per share | 0 | -0.01 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-01-31 for Q1
Metric | History | 2022-01-31 | 2022-04-30 | 2022-07-31 | 2022-10-31 | 2023-01-31 |
---|---|---|---|---|---|---|
Revenue per share | 0 | 0 | 0 | 81.29 | 0 | |
Net income per share | -0.13 | -0.12 | -0.09 | -0.11 | -0.07 | |
Operating cash flow per share | -0.04 | -0.08 | -0.05 | -0.05 | -0.06 | |
Free cash flow per share | -0.04 | -0.08 | -0.05 | -0.05 | -0.06 | |
Cash per share | 1.15 | 1.07 | 1.04 | 0.98 | 0.9 | |
Book value per share | 1.13 | 1.07 | 1.04 | 0.96 | 0.9 | |
Tangible book value per share | 1.1 | 1.04 | 1.01 | 0.93 | 0.87 | |
Share holders equity per share | 1.13 | 1.07 | 1.04 | 0.96 | 0.9 | |
Interest debt per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Market cap | 98.81M | 97.99M | 118.15M | 170.09M | 135.12M | |
Enterprise value | 69.28M | 70.5M | 94.13M | 157.96M | 125.54M | |
P/E ratio | -6.45 | -6.92 | -10.93 | -12.52 | -15.93 | |
Price to sales ratio | 0 | 0 | 0 | 0.07 | 0 | |
POCF ratio | -82.55 | -42.5 | -84.63 | -106.78 | -67.97 | |
PFCF ratio | -82.55 | -42.5 | -84.63 | -106.78 | -67.97 | |
P/B Ratio | 2.91 | 3.05 | 3.73 | 5.86 | 4.86 | |
PTB ratio | 2.91 | 3.05 | 3.73 | 5.86 | 4.86 | |
EV to sales | 0 | 0 | 0 | 0.06 | 0 | |
Enterprise value over EBITDA | -17.9 | -19.7 | -33.77 | -43.9 | -49.33 | |
EV to operating cash flow | -57.88 | -30.57 | -67.43 | -99.16 | -63.15 | |
EV to free cash flow | -57.88 | -30.57 | -67.43 | -99.16 | -63.15 | |
Earnings yield | -0.04 | -0.04 | -0.02 | -0.02 | -0.02 | |
Free cash flow yield | -0.01 | -0.02 | -0.01 | -0.01 | -0.01 | |
Debt to equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Debt to assets | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net debt to EBITDA | 7.63 | 7.68 | 8.62 | 3.37 | 3.76 | |
Current ratio | 19.58 | 27.39 | 22.01 | 14.83 | 22.81 | |
Interest coverage | -3.88K | -3.59K | -127.14 | -45.11 | -12.65 | |
Income quality | 0.31 | 0.64 | 0.5 | 0.45 | 0.84 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 1.8 | 1.68 | 1.44 | 1.55 | 1.18 | |
ROIC | 0.15 | 0.16 | 0.17 | -0.64 | -0.27 | |
Return on tangible assets | -0.11 | -0.11 | -0.08 | -0.11 | -0.07 | |
Graham Net | 1.08 | 1.02 | 0.99 | 0.9 | 0.85 | |
Working capital | 33.21M | 31.37M | 30.87M | 28.16M | 26.87M | |
Tangible asset value | 33.24M | 31.41M | 30.91M | 28.2M | 26.91M | |
Net current asset value | 33M | 31.17M | 30.68M | 27.99M | 26.71M | |
Invested capital | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Average receivables | 0 | 0 | 0 | 0 | 73.5K | |
Average payables | 320.1K | 298.5K | 160K | 246K | 187.5K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 0 | 0 | 0 | 0 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | -0.11 | -0.11 | -0.09 | -0.12 | -0.08 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ANIX Frequently Asked Questions
What is Anixa Biosciences, Inc. stock symbol ?
Anixa Biosciences, Inc. is a US stock , located in San jose of Ca and trading under the symbol ANIX
Is Anixa Biosciences, Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $8. The lowest prediction is $8 and the highest is $8
What is ANIX stock prediction ?
What is Anixa Biosciences, Inc. stock quote today ?
Anixa Biosciences, Inc. stock price is $3.4437 today.
Is Anixa Biosciences, Inc. stock public?
Yes, Anixa Biosciences, Inc. is a publicly traded company.